Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Exelixis
Scientific Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy